TY - JOUR
T1 - Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined
T2 - A naturalistic long-term follow-up study
AU - Kimiagar, Itzhak
AU - Dobronevsky, Evgenia
AU - Prokhorov, Tatiana
AU - Miniovitz, Ala
AU - Rabey, Jose M.
PY - 2012/4
Y1 - 2012/4
N2 - Tardive dyskinesia (TD) is a complex involuntary movement disorder affecting about 23% of neuroleptic- treated patients. Our objective was to retrospectively analyze a combination of tetrabenazine (TBZ), clonazepam (CLONAZ) and clozapine (CLOZ) used simultaneously for TD in psychotic patients. Six patients with severe, unsuccessfully controlled TD were referred for treatment (mean age 51.5 years; three male; four schizophrenics; one bipolar disease; one borderline personality disorder). They were being treated with neuroleptics (classic, three; risperidone, two; olanzapine, one) and developed severe neck and buccolingual dyskinesias. At our clinic, all of them were treated simultaneously with TBZ (mean dose 141.6 mg); CLONAZ (mean dose 4.3 mg); and CLOZ (mean dose 125 mg). In parallel, we stopped the offending medication. With 1 week, we observed a very impressive improvement in symptoms and within 1 month all the patients were free of symptoms. The mean observation period was 4 years. The combination of TBZ, CLONAZ and CLOZ is a rapid and beneficial option for the management of TD. An augmentation effect probably played a role in the rapid alleviation of symptomatology.
AB - Tardive dyskinesia (TD) is a complex involuntary movement disorder affecting about 23% of neuroleptic- treated patients. Our objective was to retrospectively analyze a combination of tetrabenazine (TBZ), clonazepam (CLONAZ) and clozapine (CLOZ) used simultaneously for TD in psychotic patients. Six patients with severe, unsuccessfully controlled TD were referred for treatment (mean age 51.5 years; three male; four schizophrenics; one bipolar disease; one borderline personality disorder). They were being treated with neuroleptics (classic, three; risperidone, two; olanzapine, one) and developed severe neck and buccolingual dyskinesias. At our clinic, all of them were treated simultaneously with TBZ (mean dose 141.6 mg); CLONAZ (mean dose 4.3 mg); and CLOZ (mean dose 125 mg). In parallel, we stopped the offending medication. With 1 week, we observed a very impressive improvement in symptoms and within 1 month all the patients were free of symptoms. The mean observation period was 4 years. The combination of TBZ, CLONAZ and CLOZ is a rapid and beneficial option for the management of TD. An augmentation effect probably played a role in the rapid alleviation of symptomatology.
KW - Clonazepam
KW - Clozapine
KW - Combined treatmen
KW - Tardive dyskinesia
KW - Tetrabenazine
UR - http://www.scopus.com/inward/record.url?scp=84862515671&partnerID=8YFLogxK
U2 - 10.1007/s00415-011-6235-2
DO - 10.1007/s00415-011-6235-2
M3 - Article
C2 - 22068977
AN - SCOPUS:84862515671
SN - 0340-5354
VL - 259
SP - 660
EP - 664
JO - Journal of Neurology
JF - Journal of Neurology
IS - 4
ER -